Director/PDMR Shareholding

RNS Number : 3835D

Circassia Pharmaceuticals Plc

27 March 2014

 



For immediate release

Circassia Pharmaceuticals plc

Directors' Exercise of Options

Oxford, UK - 27 March 2014: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a clinical-stage specialty biopharmaceutical company, announces that two of the Company's Directors have exercised options over Ordinary Shares of 0.08p each under the Company's EMI Share Option Scheme 2007 (the "EMI Scheme"). 

As with all of the Ordinary Shares held by the Directors, the resulting shares issued are subject to a 12-month lock-up period from 13 March 2014 in relation to the Company's initial public offering.

			Interest after option exercise
Director / PDMR	Title	Number of Options Exercised at a price of 0.08p each	Number of Ordinary Shares	% of total issued share capital
Dr Rod Hafner	Senior Vice President of Research and Development	212,375	900,544	0.48%
Charles Swingland	Non-Executive Director	535,375	5,721,677	3.03%

In addition, a further 616,125 new Ordinary Shares have been issued to employees of the Company who are not Directors or persons discharging managerial responsibilities (PDMRs), pursuant to the exercise of options under the EMI Scheme.

Following the issuance of the total of 1,363,875new Ordinary Shares, the Company today has 188,786,254 Ordinary Shares in issue, each with equal voting rights. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information, please contact:
Circassia Pharmaceuticals plc Julien Cotta, Company Secretary	[phone]

 

END

 

 

RDSBLGDXDSDBGSR